NZ333780A - Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases - Google Patents

Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases

Info

Publication number
NZ333780A
NZ333780A NZ333780A NZ33378097A NZ333780A NZ 333780 A NZ333780 A NZ 333780A NZ 333780 A NZ333780 A NZ 333780A NZ 33378097 A NZ33378097 A NZ 33378097A NZ 333780 A NZ333780 A NZ 333780A
Authority
NZ
New Zealand
Prior art keywords
diseases
genes
vaccine formula
treating dog
polynucleotide vaccine
Prior art date
Application number
NZ333780A
Other languages
English (en)
Inventor
Jean-Christophe Audonnet
Annabelle Bouchardon
Michel Riviere
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ333780(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Sas filed Critical Merial Sas
Priority to NZ506427A priority Critical patent/NZ506427A/en
Publication of NZ333780A publication Critical patent/NZ333780A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ333780A 1996-07-19 1997-07-15 Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases NZ333780A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ506427A NZ506427A (en) 1996-07-19 1997-07-15 A canidae vaccine comprising the rabies G gene under the control of the CMV-IE promoter

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609401A FR2751227B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
PCT/FR1997/001316 WO1998003199A1 (fr) 1996-07-19 1997-07-15 Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives

Publications (1)

Publication Number Publication Date
NZ333780A true NZ333780A (en) 2000-10-27

Family

ID=9494495

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333780A NZ333780A (en) 1996-07-19 1997-07-15 Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases

Country Status (17)

Country Link
US (2) US6228846B1 (enExample)
EP (1) EP0954332B2 (enExample)
JP (1) JP2000515521A (enExample)
KR (3) KR20000067866A (enExample)
AR (1) AR034997A1 (enExample)
AU (1) AU733563B2 (enExample)
BR (1) BR9710509A (enExample)
CA (1) CA2260273C (enExample)
CZ (1) CZ300385B6 (enExample)
DE (1) DE69731309T3 (enExample)
FR (1) FR2751227B1 (enExample)
NZ (1) NZ333780A (enExample)
PL (1) PL190150B1 (enExample)
RU (1) RU2319504C2 (enExample)
TW (1) TW587942B (enExample)
WO (1) WO1998003199A1 (enExample)
ZA (1) ZA976284B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US7294338B2 (en) * 1996-07-19 2007-11-13 Merial Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
CA2223029A1 (en) 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
EP0863151A1 (en) * 1997-02-12 1998-09-09 Akzo Nobel N.V. "Canine parvovirus dna vaccines"
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
BR0011732B1 (pt) * 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
ATE303821T1 (de) * 2001-02-15 2005-09-15 Indian Inst Scient Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1575613A1 (en) * 2002-12-19 2005-09-21 Akzo Nobel Trivalent vaccine with maternal antibody transfer via the milk
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
EP1668112A4 (en) 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
CA2556911C (en) 2004-02-19 2013-07-30 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
ES2343270T3 (es) 2005-04-25 2010-07-27 Merial Ltd. Vacunas contra el virus nipah.
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7767686B2 (en) * 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
US7455844B2 (en) 2006-03-29 2008-11-25 Merial Limited Vaccine against streptococci
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
EP3213766A1 (en) 2009-12-28 2017-09-06 Merial Ltd. Recombinant ndv antigen and uses thereof
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2011112945A2 (en) 2010-03-12 2011-09-15 Merial Limited Foot and mouth disease virus recombinant vaccines and uses thereof
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
JP6407714B2 (ja) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
NZ618125A (en) 2011-05-27 2016-03-31 Merial Ltd Genetic vaccines against hendra virus and nipah virus
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
HUE033858T2 (en) 2012-02-14 2018-01-29 Merial Inc Rotavirus unit vaccines and method for their preparation and use
EA032389B1 (ru) 2012-02-14 2019-05-31 Мериал, Инк. Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
NZ703297A (en) 2012-06-13 2016-04-29 Merial Ltd Reassortant btv and ahsv vaccines
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
CN105517569A (zh) * 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
US10010605B2 (en) 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
PH12017502380B1 (en) 2015-06-23 2022-10-26 Merial Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
PH12018500372B1 (en) 2015-08-20 2023-03-15 Merial Inc Fcv recombinant vaccines and uses thereof
AR106026A1 (es) 2015-09-29 2017-12-06 Merial Inc Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
JP6797206B2 (ja) 2015-11-23 2020-12-09 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｆｍｄｖ及びｅ２融合タンパク質並びにその使用
RU2626605C2 (ru) * 2015-11-25 2017-07-28 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая (рекомбинантная) ДНК-конструкция, содержащая кодон-оптимизированный ген гликопротеина (белка G) вируса бешенства с консенсусной аминокислотной последовательностью, которая составлена с учетом аминокислотных последовательностей белка G, выделяемого из штаммов вируса бешенства, циркулирующих на территории Российской Федерации
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN108704128B (zh) * 2018-05-15 2022-06-21 青岛农业大学 一种犬瘟热细小病毒二联亚单位疫苗
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
RU2707544C1 (ru) * 2018-12-28 2019-11-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая конструкция на основе оптимизированного гена консенсусного гликопротеина вируса бешенства для профилактики бешенства
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CN116735873B (zh) * 2023-08-09 2023-10-31 北京纳百生物科技有限公司 特异性结合犬细小病毒vp2蛋白的单克隆抗体在检测试剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU56248A1 (enExample) * 1968-06-11 1970-01-15
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
WO1997040163A1 (en) 1996-04-19 1997-10-30 Metin Colpan Nucleic acid vaccination for parvoviral infections
WO1997041236A1 (en) 1996-04-29 1997-11-06 Andreas Zurbriggen Polynucleotide vaccine against canine distemper
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
CA2223029A1 (en) 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
IT1292422B1 (it) * 1997-06-26 1999-02-08 Agip Petroli Reattore a bolle con draft tube e procedimento per la rigenerazione del catalizzatore in esso contenuto
US6063385A (en) * 1997-11-07 2000-05-16 Wisconsin Alumni Research Foundation DNA vaccine for parvovirus

Also Published As

Publication number Publication date
TW587942B (en) 2004-05-21
EP0954332B1 (fr) 2004-10-20
KR100620302B1 (ko) 2006-09-06
CZ15899A3 (cs) 1999-05-12
RU2002132833A (ru) 2005-01-20
CA2260273A1 (en) 1998-01-29
PL190150B1 (pl) 2005-11-30
CA2260273C (en) 2010-12-21
DE69731309D1 (de) 2004-11-25
DE69731309T3 (de) 2015-06-03
JP2000515521A (ja) 2000-11-21
EP0954332A1 (fr) 1999-11-10
KR20050087885A (ko) 2005-08-31
DE69731309T2 (de) 2005-11-17
US6228846B1 (en) 2001-05-08
ZA976284B (en) 1999-01-19
AU3699397A (en) 1998-02-10
AR034997A1 (es) 2004-04-14
PL331246A1 (en) 1999-07-05
RU2319504C2 (ru) 2008-03-20
EP0954332B2 (fr) 2014-12-31
WO1998003199A1 (fr) 1998-01-29
BR9710509A (pt) 1999-08-17
KR20000067866A (ko) 2000-11-25
US20010009959A1 (en) 2001-07-26
KR20060013432A (ko) 2006-02-09
CZ300385B6 (cs) 2009-05-06
US6586412B2 (en) 2003-07-01
FR2751227B1 (fr) 1998-11-27
AU733563B2 (en) 2001-05-17
FR2751227A1 (fr) 1998-01-23

Similar Documents

Publication Publication Date Title
RU2002132833A (ru) Формула вакцины против патологий собак
WO1998003200A3 (fr) Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
AR007864A1 (es) Formula de vacuna porcina, su utilizacion y kit de vacunacion que la contiene.
DE69730839T2 (de) Hühner polynukleotide impfstoff-formulierung
CA2261345A1 (en) Feline polynucleotide vaccine formula
ATE419368T1 (de) System zum transfer und zur expression von heterologen genen ins knochenmark in vivo
JP2008143900A (ja) ウマの予防用ポリヌクレオチドワクチン製剤
IL114566A0 (en) Compositions containing mucleic acids their preparation and uses
DK0598816T3 (da) Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
NO923395L (no) Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener
GR990300042T1 (en) Subunit respiratory syncytial virus vaccine preparation
DE69732029D1 (de) Dna enthaltende impfstoffen
IL112261A (en) RIBOZYMES TARGETING THE MoMLV PSI PACKAGING SEQUENCE AND THE HIV TAT SEQUENCE
Rao et al. Comparative studies on tomato aspermy and cucumber mosaic viruses. VI. Partial compatibility of genome segments from the two viruses
AU1521492A (en) Recombinant varicella-zoster virus and process for constructing same
RU99103298A (ru) Формула полинуклеотидной вакцины против патологий собак, в частности, респираторных патологий и патологий пищеварения
RU99103293A (ru) Формула полинуклеотидной вакцины против респираторных патологий и патологий репродукции свиней
EP0648841A3 (en) Genomic DNA for human cholesterol 7-alpha hydroxylase and method of using it.
EP0777730A4 (en) DNA VECTOR FOR BONE-SPECIFIC GENE EXPRESSION
DE3885579D1 (de) Densonukleosis hervorrufende Plasmide, Verfahren zu deren Herstellung sowie dessen Verwendung zur Bekämpfung von Insektenplagen.
RU99103209A (ru) Формула кошачей полинуклеотидной вакцины
Terzić et al. Proportion of CD4a+ CD8a+ and wCD21+ cells in peripheral blood of pigs vaccinated against classical swine fever
TH32901A (th) สูตรพอลินิวคลีโอไทด์วัคซีนต่อพยาธิสภาพทางระบบสืบพันธุ์และทางเดินหายใจของสุกร
TH16076B (th) สูตรพอลินิวคลีโอไทด์วัคซีนต่อพยาธิสภาพทางระบบสืบพันธุ์และทางเดินหายใจของสุกร
RU99103671A (ru) Формула полинуклеотидной вакцины, в частности, против респираторных патологий крупного рогатого скота

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired